GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syros Pharmaceuticals Inc (FRA:0S90) » Definitions » Inventories, Other

Syros Pharmaceuticals (FRA:0S90) Inventories, Other : €0.00 Mil (As of Sep. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Syros Pharmaceuticals Inventories, Other?

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. Syros Pharmaceuticals's other inventories for the quarter that ended in Sep. 2024 was €0.00 Mil.


Syros Pharmaceuticals Inventories, Other Historical Data

The historical data trend for Syros Pharmaceuticals's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syros Pharmaceuticals Inventories, Other Chart

Syros Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Other
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Syros Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Inventories, Other Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Syros Pharmaceuticals Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.


Syros Pharmaceuticals Business Description

Traded in Other Exchanges
Address
35 CambridgePark Drive, 4th Floor, Cambridge, MA, USA, 02140
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.

Syros Pharmaceuticals Headlines

No Headlines